DOP033: Severely active Ulcerative Colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomesECCO'17 Barcelona 2017
1
DOP034: Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn’s Disease patients treated with adalimumab for prevention of postoperative recurrenceECCO'17 Barcelona 2017
1
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBDECCO'17 Barcelona 2017
1
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylationECCO'17 Barcelona 2017
1
DOP037: A model for prediction of early surgery and complications in paediatric Crohn’s Disease; Results of the prospective GROWTH CD studyECCO'17 Barcelona 2017
1
DOP039: Postoperative infectious complications in Crohn’s Disease: results from PRACTICROHN studyECCO'17 Barcelona 2017
1
DOP040: Postoperative surgical recurrence in Crohn’s Disease decreases significantly in the biologic eraECCO'17 Barcelona 2017
1
DOP041: Prepouch ileitis after ileal pouch anal anastomosis for Ulcerative Colitis: Patterns of presentation and risk factors for failure of treatmentECCO'17 Barcelona 2017
1
DOP042: Omentectomy is not necessary during laparoscopic total coloproctectomy and ileal Pouch-anal anastomosis for inflammatory bowel disease. A comparative study in 247 consecutive patients from 4 expert centresECCO'17 Barcelona 2017
1
DOP043: High risk of pouch dysplasia in IBD-PSC patients following total proctocolectomyECCO'17 Barcelona 2017
1
DOP044: Relationship between microbiota and development of early postoperative Crohn’s Disease recurrenceECCO'17 Barcelona 2017
1
DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn’s DiseaseECCO'17 Barcelona 2017
1
DOP047: Early fibrostenosis in Crohn’s Disease is associated with multiple susceptibility loci on Immunochip analysisECCO'17 Barcelona 2017
1
DOP048: PROFILE trial: Predicting outcomes for Crohn’s Disease using a molecular biomarkerECCO'17 Barcelona 2017
1
DOP049: Inflammatory dyskinesis: defects of NF-κ B dynamic behaviour as a new potential biomarker for personalized medicine in Inflammatory Bowel DiseaseECCO'17 Barcelona 2017
1
DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn’s DiseaseECCO'17 Barcelona 2017
1
DOP052: Molecular response to Ustekinumab in moderate-to-severe Crohn’s Disease by serum protein and biopsy gene expression analysis: Results from Ustekinumab phase 3 studiesECCO'17 Barcelona 2017
1